Cancer patients as well as patients with conditions such as cystic fibrosis and chronic pancreatitis are now confronted with an acute shortage of an essential medication—Creon. This pancreatic enzyme replacement therapy (PERT) is crucial to digesting food, one of the most fundamental of human activities which becomes all but impossible for those with pancreatic insufficiency.

The consequences are frightening- patients are forgoing meals, dividing up doses, and driving more than 30 miles just to receive the capsules. The effect is not just nutritional but life-threatening, because not being able to properly digest food can make a person vulnerable to infection, make them weaker, and restrict access to life-saving treatment like chemotherapy.

Creon is the brand name of pancreatic enzyme replacement therapy that is used to manage exocrine pancreatic insufficiency (EPI)—a disease in which the pancreas is unable to produce enzymes to help digest food. This inability can be due to a variety of reasons, such as pancreatic cancer, cystic fibrosis, chronic pancreatitis, and complications after surgery like gastric-bypass or pancreatic surgery.

For individuals with EPI, Creon® is not merely a supportive therapy—it is a lifeline. It allows them to extract nutrition from food and sustain body weight, energy, and immune capacity. Without it, patients experience persistent diarrhea, abdominal pain, malnutrition, and ultimately, reduced quality of life and survivability.

The Government in the UK has prolonged the Serious Shortage Protocol (SSP) for Creon until November 2025, enabling pharmacists to dispense a reduced quantity without a fresh prescription. Although the policy tries to make things more accessible, this is a short-term solution to an ongoing and hazardous shortage.

One survey carried out by the National Pharmacy Association (NPA), surveying more than 300 pharmacies, shows a dire picture. A whopping 96% of these pharmacies are struggling to get Creon, the essential pancreatic enzyme replacement therapy. Additionally, 89% have the same shortages with other drugs like Nutrizym and Pancrex. This shortage is making many patients go distances of over 30 miles just to get a pharmacy that will fill their prescriptions. Even more alarming, many patients are said to be skipping meals or cutting their doses in order to stretch their short supplies, jeopardizing their health and wellbeing in the process.

The shortage is primarily due to "European-wide supply issues" and production limitations on the drug that have caused interruptions in the manufacture and distribution of Creon, as reported by the Department of Health and Social Care. The interruptions are not specific to Creon but point to systemic weaknesses in pharmaceutical production.

In Creon's case, though, the end result is worse. Unlike certain drugs that can be skipped or substituted for others, Creon® is instantly vital with each patient meal. There is no "respite" from taking it, and even temporary discontinuation can cause health emergencies.

How is the Shortage of the Drug Affecting Cancer Patients?

The psychological and physical strain on the patients cannot be estimated. As Alfie Bailey-Bearfield, Pancreatic Cancer UK's Head of Influencing & Health Improvement, stressed, "It's completely unacceptable that they are still taking desperate steps which risk their health, wellbeing, and their suitability for treatment."

Patients going without meals in order to cut corners on enzyme capsules put themselves at significant risk of malnutrition and severe weight loss. Not only does this compromise the immune response of the body, it lowers tolerance to chemotherapy, effectively excluding patients from life-sustaining or curative therapy. The medical risk is not abstract—it's real and measurable.

What is EPI?

Exocrine Pancreatic Insufficiency (EPI) is more prevalent than many people know. In the UK alone, approximately 61,000 patients need pancreatic enzyme therapy. Reasons are:

• Pancreatic cancer (especially advanced)
• Cystic fibrosis
• Chronic and acute pancreatitis
• Pancreatic surgery or gastric bypass
• Untreated celiac disease or inflammatory bowel disease

EPI results in undigested food entering the colon, leading to bloating, gas, cramps, and diarrhea. With time, the nutrient deficiencies cause weight loss, bone loss, and even increased cardiovascular risk. In children, it impairs growth and development.

Unlike regular prescriptions, Creon is not prescribed with a set amount. It has to be individualized for each patient, for each meal, and even for each snack. The dosing is 3,000 to 36,000 enzyme units per capsule. For comparison, a normal pancreas will release up to 720,000 units for a small meal.

Patients are instructed to self-regulate according to their intake, so that a consistent and plentiful source becomes not only the preferred but also the necessary mode of correct dosing. Under shortages, this individualized dosing is a luxury many cannot enjoy.

Healthcare providers and patient advocacy groups alike are demanding immediate government action. Bailey-Bearfield and Picard have issued public calls for a strategic restructuring to solve manufacturing constraints and enhance distribution systems.

"This crisis continues to put people's health at risk, and they cannot afford to wait any longer," Bailey-Bearfield implored.

It takes not only stockpiling but also long-term planning, such as investment in alternative manufacturing hubs, local production incentives, and better global supply chain coordination.

Vitruvias Therapeutics’ thyroid medication, recalled nationwide in August, has been elevated to the highest risk level by the US FDA.

The recall was issued because the medication may be superpotent, potentially causing hyperthyroidism (overactive thyroid).

On Wednesday, the FDA updated the recall to Class I, its most serious recall classification. It applies when there is a “reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.”

Which Thyroid Tablets Have Been Recalled?

Also read: US Cancer Death Rates Fall For Men, Women: Lung Cancer Progress Drives Decline

The affected product is:

• Vitruvias Thyroid Tablets USP 30 mg
• Lot number: 504950
• Expiration date: September 30, 2026

In its August 24 recall notice, the company said the tablets were potentially superpotent.

Risks of Superpotent Thyroid Medicines

Millions of people with hypothyroidism rely on thyroid tablets every day to replace hormones their bodies cannot produce.

However, taking superpotent thyroid tablets can cause hyperthyroidism (overactive thyroid). It can force the body's metabolism into overdrive, speeding up organs and bodily functions.

Left untreated, this constant strain can cause serious health complications across multiple systems in the body.

In addition, people taking the medication can be at risk of

• weight loss,
• heat intolerance,
• fatigue,
• nervousness,
• muscle weakness,
• hypertension,
• chest pain,
• rapid heart rate,
• heart rhythm disturbances.

The lot was distributed nationwide in the US to Vitruvias Therapeutics’ direct accounts between January 31 and September 30, 2025. Of 3,655 units released, 1,955 were sold.

Read More: FDA Recalls Popular Thyroid Medication: What Levothyroxine Users Need to Know

Who Is At Greater Risk?

The company identified the following groups as being at greater risk from superpotent thyroid tablets:

• Elderly people
• Pregnant women
• Infants

Excess thyroid hormones in older adults have been associated with adverse outcomes, particularly those affecting the heart.

Vitruvias Therapeutics said it has not received any reports of adverse events known to be linked to the recall.

The company is notifying wholesalers to stop distributing the recalled product and arranging for its destruction.

What Should Patients Do?

Patients taking Thyroid, USP from Lot 504950 should not stop taking it without first contacting their healthcare provider for guidance and/or a replacement prescription.

Hypothyroidism vs Hyperthyroidism

Speaking to HealthandMe, Dr Shruti Kotangale, Consultant Gynaecologist, Obstetrician and Infertility Expert at AIMS Hospital, Dombivli, explained that both conditions are commonly seen in women.

Hypothyroidism occurs when the thyroid is underactive. Symptoms can include tiredness, weight gain, dry skin, hair fall, constipation, feeling cold, a slow heartbeat and low mood or depression.

Hyperthyroidism occurs when the thyroid is overactive. Symptoms may include weight loss, a fast heartbeat, sweating, anxiety, tremors, irritability, frequent bowel movements and difficulty sleeping.

Women should seek medical attention and manage these symptoms without delay.

Common Symptoms Of Thyroid Disorders

Thyroid disorders may cause a range of symptoms, including:

• Fatigue
• Cognitive changes
• Gastrointestinal problems
• Sensitivity to cold
• Skin and hair changes
• Weight changes

How Is Thyroid Disease Diagnosed?

Diagnosis may involve:

• Physical examination: To check for swelling or nodules in the neck.
• Blood tests: These may measure TSH, T4 and T3 levels, along with thyroid antibodies when conditions such as Hashimoto’s disease or Graves’ disease are suspected.
• Ultrasound or thyroid scans may also be used to assess the thyroid’s structure.

American racing champion and NASCAR Hall of Famer Darrell Waltrip has been diagnosed with Frontotemporal Dementia (FTD), his family has announced.

The 79-year-old former NASCAR driver and broadcaster will be stepping further away from public life following the diagnosis.

According to his family, Waltrip has FTD, which is being complicated by possible chronic traumatic encephalopathy (CTE), which they believe may be linked to injuries sustained during his racing career from 1972 to 2000.

“We wanted to share a health update with all of Darrell’s friends and fans who have supported him throughout his racing career. Recently, Darrell has been diagnosed with Frontotemporal Degeneration (FTD) complicated by possible Chronic Traumatic Encephalopathy (CTE) — likely from injuries incurred during his racing career,” the family said in a statement.

The family said Waltrip currently has only “minor noticeable symptoms” and is “happy and otherwise healthy,” spending time with his wife, Stevie, and their two daughters.

Why Can Repeated Head Injuries Raise CTE Concerns?

Chronic traumatic encephalopathy (CTE) is a progressive brain disease believed to be associated with repeated head injuries. It has most commonly been studied in contact-sport athletes and military personnel exposed to repeated head trauma.

Experts are still studying how the number and severity of head injuries contribute to CTE risk. Importantly, not everyone exposed to repeated head injuries develops CTE, and the condition can currently be definitively diagnosed only after death through examination of brain tissue.

A 2026 study led by researchers at Boston University and Harvard Medical School found that roughly one in four former NFL players who died between 2016 and 2021 had CTE.

CTE And Racing

Although CTE has historically received considerable attention in American football and other contact sports, repeated head impacts can occur in motorsports as well.

Waltrip is not alone. NASCAR Hall of Famer Fred Lorenzen was diagnosed with CTE by researchers after he died in 2024.

What Is Frontotemporal Degeneration?

Read More: The First Symptom of Bruce Willis’ Frontotemporal Dementia That Left His Wife Emma Heming Stunned

Frontotemporal degeneration, also known as frontotemporal dementia (FTD), refers to a group of brain disorders that primarily affect the frontal and temporal lobes.

These areas are involved in personality, behavior, language, and other functions. Unlike Alzheimer's disease, memory loss may not be the first or most prominent symptom of FTD.

FTD can develop at a younger age than many other forms of dementia, sometimes affecting people in their 40s or 50s.

The condition can cause changes in:

• Personality and behavior
• Judgment and decision-making
• Emotional responses and empathy
• Speech and language
• Movement and coordination

What Are The Symptoms Of FTD?

Symptoms vary depending on which areas of the brain are most affected and generally worsen over time.

Behavioral Symptoms

• Personality and behavior changes
• Loss of empathy
• Poor judgment and impulsivity
• Socially inappropriate behavior
• Apathy or loss of interest
• Repetitive or compulsive behavior

• Difficulty finding words
• Trouble understanding speech or writing
• Difficulty naming objects
• Increasing difficulty speaking

• Tremors or stiffness
• Muscle weakness or spasms
• Poor balance and falls
• Difficulty swallowing
• Changes in speech or movement

Darrell Waltrip's Racing Legacy

Waltrip is one of NASCAR's most accomplished drivers, with 84 Cup Series victories and three Cup Series championships.

He won the Daytona 500 in 1989 and the Southern 500 in 1992. He also won the Coca-Cola 600 five times, making him the winningest driver in the race's history.

Waltrip later became a familiar voice in NASCAR broadcasting, working as a commentator for many years.

The UK NHS is set to review around 4,500 more breast cancer cases dating back to 2015 after a review found delayed diagnoses and 20 cases involving unnecessary breast removal surgery.

Hundreds of patients suffered harm under County Durham and Darlington NHS Foundation Trust in north-east England., according to the review.

The Trust has apologized and is using specialists from other hospitals to determine whether more women underwent unnecessary operations or received poor care.

"The trust will complete the reviews already under way covering care between January 2023 and February 2025. It will then look back one year at a time, starting with patients treated in 2022 and working backwards towards 2015," it said in a statement.

Review Could Cover 4,500 Cases

Also read: Alcohol-Linked Cancer Deaths Doubled In US: Colorectal Leads In Men, Breast Leads In Women

Board chair Alison Marshall apologized to women and families affected by the failings.

"I would like to offer a sincere apology to all the women and their families who have been affected by the failings in our breast services," she said, according to the BBC.

"I can't imagine the impact that has had."

She said the Trust could "not turn back the clock" but would be "open, honest and transparent" about the failings.

Chief nurse Gill Hunt said concerns were first raised in 2015 following a "service reconfiguration" and the loss of breast surgical trainee posts.

Till September 2, 2026, a total of 539 cases had been reviewed, and is expected to examine around 4,500 cases if it extends back to 2015.

The Trust said each year's findings will be "carefully considered" before it moves to the next earlier year. As per the report, the review could take five years, with women treated in 2015 potentially having their cases reviewed as late as 2031.

The admission came after the BBC reported last year that more than 200 patients were found to have suffered harm at the CDDFT.

"We have heard again today about the profound and lasting impact that failings in our breast services have had on women and their families," said Chief executive Steve Russell.

"We remain deeply sorry for the harm and distress caused, and for the times when, as a Trust, we should have listened more carefully, asked more questions and acted sooner," Russell added.

About 640 patients have contacted a special helpline seeking a review of their cases. The current review cost about £523,000 in its first year and involved nine reviewers examining around 80 cases a month.

20 Women Had Unnecessary Mastectomies

Read More: FDA Approves New Breast Cancer Treatment That Targets Resistance Before Cancer Progresses

About 514 cases reviewed by the trust so far, between January 2023 and February 2025, alongside the cases of 640 former patients who contacted a dedicated helpline.

Of the 514 cases, 315 patients have been found to have suffered harm, including 77 who were significantly harmed. One patient is known to have died.

The Trust was found to have a high number of mastectomies compared with other NHS trusts, with operations carried out "too quickly".

Breast Cancer Burden In UK

Breast cancer is the most common cancer in the UK, accounting for roughly 15% of all new cancer cases.

Around 60,763 new cases are diagnosed each year, according to Breast Cancer UK. An estimated 14,000-15,000 mastectomies are performed annually in the UK.

What Is A Mastectomy?

A mastectomy is surgery to remove the whole breast. Depending on the cancer, nearby lymph nodes and surrounding tissue may also be removed. It may be performed on one or both breasts depending on the type of cancer and individual risk factors.

Some patients may undergo breast reconstruction after a mastectomy to restore breast shape and symmetry.